Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
28.42
-1.43 (-4.79%)
At close: Apr 10, 2026, 4:00 PM EDT
28.52
+0.10 (0.35%)
After-hours: Apr 10, 2026, 4:04 PM EDT
Assembly Biosciences Employees
Assembly Biosciences had 73 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
73
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$990,452
Profits / Employee
-$83,863
Market Cap
450.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 73 | 0 | - |
| Dec 31, 2024 | 73 | 8 | 12.31% |
| Dec 31, 2023 | 65 | -3 | -4.41% |
| Dec 31, 2022 | 68 | -34 | -33.33% |
| Dec 31, 2021 | 102 | -37 | -26.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| ADC Therapeutics | 193 |
| Absci | 140 |
| Verastem | 102 |
| enGene Holdings | 82 |
| Lexeo Therapeutics | 59 |
| AgomAb Therapeutics NV | 58 |
| Atea Pharmaceuticals | 55 |
ASMB News
- 2 days ago - Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 - GlobeNewsWire
- 23 days ago - Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 3 months ago - Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - Business Wire
- 4 months ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 5 months ago - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 5 months ago - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - GlobeNewsWire
- 6 months ago - Assembly Biosciences Announces Upcoming Investor Conference Participation - GlobeNewsWire
- 6 months ago - Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe - GlobeNewsWire